Independant Safety Panel may of suggested data indicates an early stop on efficacy .
MSB then has decision to make after talking to FDA and asking if the amount of data gathered is sufficient for approval or only enough for emergency use?
Does MSB and NIH continue trial to gather more data?
Could be the circumstances here?
Maybe SI notified by a Major Pharma of intention to lodge a takeover? Friendly or Hostile (first of a few I hope as value setting).
Could be another?
Ann: Trading halt, page-94
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.030(1.90%) |
Mkt cap ! $1.832B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.65 | $1.59 | $7.014M | 4.343M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 342 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 54534 | 8 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |